Legal Representation
Attorney
Elizabeth A. Walker
USPTO Deadlines
Next Deadline
59 days remaining
NOA E-Mailed - SOU Required
Due Date
October 01, 2025
Extension Available
Until April 01, 2026
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 1, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 4, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 4, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 29, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 15, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 15, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 15, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 15, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 29, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 27, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 27, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 28, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Aug 28, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 31, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 31, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 31, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 24, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 13, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 7, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
House mark for the following, namely, Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects for treatment therefor; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
THERAPEUTICS